Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma
Authors:
- 1 March 2019
- journal article
- research article
- Published by Elsevier in European Urology Focus
- Vol. 5 (2) , 201-204
Abstract
No abstract availableKeywords
Funding Information
- Cycle for Survival (T32CA082088)
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology
This publication has 10 references indexed in Scilit:
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 2016
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)The Journal of Molecular Diagnostics, 2015
- TERT promoter mutations and telomerase reactivation in urothelial cancerScience, 2015
- Telomerase reverse transcriptase promoter mutations in primary cutaneous melanomaNature Communications, 2014
- Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with OutcomeEuropean Urology, 2014
- Telomerase Reverse Transcriptase Gene Promoter Mutations Help Discern the Origin of Urogenital Tumors: A Genomic and Molecular StudyEuropean Urology, 2014
- Comprehensive molecular characterization of urothelial bladder carcinomaNature, 2014
- Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder CancerJournal of Clinical Oncology, 2013
- TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewalProceedings of the National Academy of Sciences, 2013
- Altered Telomeres in Tumors with ATRX and DAXX MutationsScience, 2011